This article was originally published in The Gray Sheet
Pharmaceutical auto-injector devices for allergic reactions, made by Meridian Medical Technologies, are cited as a key draw of $247.8 mil. acquisition by King Pharmaceuticals. King will pay $44.50 per share in cash for the firm, a 17% premium to its Oct. 18 close of $38.15. In addition to gaining EpiPen, drug maker King plans to leverage Meridian's NDA-approved auto-injector technology in the area of homeland security. Meridian currently offers the technology to the military for use with a nerve gas antidote, as well as auto-injectors filled with morphine, diazepam and lidocaine. The Columbia, Maryland firm reported net income of $9.3 mil. for the year ended July 31 on revenues of $82.4 mil., including $4.6 mil. in sales of telemedicine and ECG devices...
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.